Altamira Therapeutics Ltd (NASDAQ:CYTO) shares, rose in value, with the stock price down by -8.86% to the previous day’s close as strong demand from buyers drove the stock to $1.44.
Actively observing the price movement in the last trading, the stock closed the session at $1.58. Referring to stock’s 52-week performance, its high was $28.40, and the low was $1.38. On the whole, CYTO has fluctuated by -38.72% over the past month.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CYTO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CYTO currently trading nearly -22.32% and -22.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.26, while the 7-day volatility ratio is showing 10.52% which for the 30-day chart, stands at 11.52%. Furthermore, Altamira Therapeutics Ltd (CYTO)’s beta value is 2.55, and its average true range (ATR) is 0.21.
A comparison of Altamira Therapeutics Ltd (CYTO) with its peers suggests the former has fared considerably weaker in the market. CYTO showed an intraday change of -8.86% in last session, and over the past year, it shrunk by -93.27%%.
Data on historical trading for Altamira Therapeutics Ltd (NASDAQ:CYTO) indicates that the trading volumes over the past 3 months, they’ve averaged 1.18 million. According to company’s latest data on outstanding shares, there are 2.24 million shares outstanding.
Nearly 0.06% of Altamira Therapeutics Ltd’s shares belong to company insiders and institutional investors own 0.34% of the company’s shares. The stock has fallen by -58.62% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CYTO stock heading into the next quarter.
